These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D. Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950 [Abstract] [Full Text] [Related]
3. The importance of high-tone audiometry in monitoring for ototoxicity. Tange RA, Dreschler WA, van der Hulst RJ. Arch Otorhinolaryngol; 1985 Dec; 242(1):77-81. PubMed ID: 3899068 [Abstract] [Full Text] [Related]
4. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. van der Hulst RJ, Dreschler WA, Urbanus NA. Ann Otol Rhinol Laryngol; 1988 Dec; 97(2 Pt 1):133-7. PubMed ID: 3281541 [Abstract] [Full Text] [Related]
5. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. De Lauretis A, De Capua B, Barbieri MT, Bellussi L, Passàli D. Scand Audiol; 1999 Dec; 28(3):139-43. PubMed ID: 10489862 [Abstract] [Full Text] [Related]
6. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ. Oncology; 2017 Dec; 93(2):75-82. PubMed ID: 28511189 [Abstract] [Full Text] [Related]
7. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL. Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860 [Abstract] [Full Text] [Related]
8. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE. J Otolaryngol; 1994 Jun; 23(3):151-9. PubMed ID: 8064951 [Abstract] [Full Text] [Related]
9. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria. Beahan N, Kei J, Driscoll C, Charles B, Khan A. Ear Hear; 2012 Jun; 33(1):104-11. PubMed ID: 21760512 [Abstract] [Full Text] [Related]
10. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner KW, Cavalli F. Invest New Drugs; 1984 Jun; 2(3):297-304. PubMed ID: 6392147 [Abstract] [Full Text] [Related]
11. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844 [Abstract] [Full Text] [Related]